The 21st century has seen substantial changes in the agents and clinical approaches to cancer chemotherapy, with corresponding improvements in prognosis for many cancers.
1 However, the longer-term balance of benefits and risks of new treatment approaches often are not well understood because clinical trials for many cancers lack sufficient sample size and long-term patient follow-up. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), a clonal hematopoietic stem cell neoplasm that can transform to AML, are rare, usually fatal complications of cancer therapy. Certain alkylating agents (eg, melphalan), platinum compounds (eg, cisplatin), and topoisomerase II inhibitors (eg, etoposide) have been reported to confer more than 5-fold increased risks for therapy-related MDS or AML (tMDS/AML), whereas other alkylating agents have lower risks (eg, cyclophosphamide), and other classes of agents, such as fluoropyrimidines (eg, fluorouracil), have no apparent association.
2-4 Radiotherapy has been associated with tMDS/AML, although the exact magnitude of risk is unclear.
5